pamlicobio.com
Products :: Pamlico Biopharma Inc.
http://pamlicobio.com/products
Pamlico BioPharma, Inc. develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. RAPIDmAb Technology – Fully Human Monoclonal Antibody Platform. Influenza (H3N2, both A & B lineages). Since 1 in 5 hospitalizations for CAP are caused by the three strains of S. pneumoniae currently targeted by our therapeutic, PneumoMab’s POC diagnostic could be utilized across the 1 million. Pamlico’s mAb mixture is targeted at S. pneumoniae,...
pamlicobio.com
Management :: Pamlico Biopharma Inc.
http://pamlicobio.com/management
Chairman and Chief Executive Officer. Clayton Duncan has over 20 years’ experience as a biopharmaceutical CEO, working with scientific founders and employees to direct research toward effective drug discovery and development. He received an MBA from the University of North Carolina at Chapel Hill and an MA from the University of California, Santa Barbara. President and Chief Operating Officer.
pamlicobio.com
About Us :: Pamlico Biopharma Inc.
http://pamlicobio.com/about-us
pamlicobio.com
Collaborators :: Pamlico Biopharma Inc.
http://pamlicobio.com/collaborators
Pamlico BioPharma has existing collaborations with leading research institutions and companies that support various aspects of our company’s research and development activities. OMRF Core Antibody Lab. Polysaccharides under partnership with Pamlico BioPharma. Judith James, M.D., Ph.D. Kenneth Smith, Ph.D. Polysaccharides (24 serotypes and cell wall polysaccharides), varicella zoster, and anthrax protective antigen. Is a biopharmaceutical contract manufacturing company specializing in the production of th...
pamlicobio.com
News :: Pamlico Biopharma Inc.
http://pamlicobio.com/news
Pamlico BioPharma receives funding from Accele Venture Partners. Pneumomab is targeted at. Recently classified as a Qualifying Pathogen under FDA’s recent GAIN Act to accelerate development of anti-infectives. If PneumoMab is indeed registered as a Qualified Infectious Disease Product, it would confer Fast-Track status on the product, and an additional 5 years of market exclusivity. About Pamlico BioPharma, Inc. For additional information please visit www.pamlicobio.com.
pamlicobio.com
Pamlico BioPharma receives funding from Accele Venture Partners :: Pamlico Biopharma Inc.
http://pamlicobio.com/pamlico-biopharma-receives-seed-funding
Pamlico BioPharma receives funding from Accele Venture Partners. Middot; Wednesday ,. Pneumomab is targeted at. Recently classified as a Qualifying Pathogen under FDA’s recent GAIN Act to accelerate development of anti-infectives. If PneumoMab is indeed registered as a Qualified Infectious Disease Product, it would confer Fast-Track status on the product, and an additional 5 years of market exclusivity. About Pamlico BioPharma, Inc. For additional information please visit www.pamlicobio.com.